
    
      A Phase III, open-label randomized, multicenter trial to compare ABI-007(Albumin-bound
      Paclitaxel)in combination with gemcitabine administered weekly to standard treatment
      (gemcitabine monotherapy) with respect to overall survival, objective tumor response rate and
      Progression Free Survival (PFS) in patients diagnosed with metastatic adenocarcinoma of the
      pancreas.
    
  